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OCT4 cooperates with distinct ATP-dependent
chromatin remodelers in naïve and primed
pluripotent states in human
Xin Huang 1,14, Kyoung-mi Park2,3,14, Paul Gontarz2,3, Bo Zhang 2,3, Joshua Pan4,5, Zachary McKenzie4,
Laura A. Fischer2,3, Chen Dong 2,3, Sabine Dietmann2,6, Xiaoyun Xing 3,7, Pavel V. Shliaha8, Jihong Yang 1,
Dan Li 1,9, Junjun Ding 9,10, Tenzin Lungjangwa11, Maya Mitalipova11, Shafqat A. Khan2,3,
Sumeth Imsoonthornruksa11,12, Nick Jensen 2,3, Ting Wang 3,7, Cigall Kadoch 4,5, Rudolf Jaenisch 11,13,
Jianlong Wang 1 ✉ & Thorold W. Theunissen 2,3 ✉

Understanding the molecular underpinnings of pluripotency is a prerequisite for optimal
maintenance and application of embryonic stem cells (ESCs). While the protein-protein
interactions of core pluripotency factors have been identiﬁed in mouse ESCs, their interactome in human ESCs (hESCs) has not to date been explored. Here we mapped the OCT4
interactomes in naïve and primed hESCs, revealing extensive connections to mammalian
ATP-dependent nucleosome remodeling complexes. In naïve hESCs, OCT4 is associated with
both BRG1 and BRM, the two paralog ATPases of the BAF complex. Genome-wide location
analyses and genetic studies reveal that these two enzymes cooperate in a functionally
redundant manner in the transcriptional regulation of blastocyst-speciﬁc genes. In contrast, in
primed hESCs, OCT4 cooperates with BRG1 and SOX2 to promote chromatin accessibility at
ectodermal genes. This work reveals how a common transcription factor utilizes differential
BAF complexes to control distinct transcriptional programs in naïve and primed hESCs.
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P

luripotency, the ability of a single cell to give rise to all cell
types found in an organism, is a fundamental characteristic
of embryonic stem cells (ESCs). Mouse and human ESCs
are both derived from the inner cell mass (ICM) of the preimplantation blastocyst but differ signiﬁcantly in their epigenomic, morphological, and transcriptomic features. Mouse ESCs
(mESCs) are marked by early developmental properties associated with naïve pluripotency1. In contrast, human ESCs
(hESCs) derived under conventional culture conditions are
developmentally more advanced and resemble mouse epiblast
stem cells (EpiSCs); thus, they are considered to represent a
primed state of pluripotency1–3. Over the past few years, speciﬁc
combinations of inhibitors and cytokines have been developed to
enable the generation of naïve hESCs by resetting primed
hESCs4–6, somatic cell reprogramming7–10, or deriving novel
naïve hESCs directly from human preimplantation embryos4,11.
Naïve hESCs offer a window into aspects of early development
that cannot be adequately modelled with primed hESCs, such as
X chromosome reactivation12,13 and the role of hominid-speciﬁc
transposable elements associated with early embryogenesis14,15.
Furthermore, recent studies indicate that naïve hESCs have a
unique predisposition to acquire extraembryonic fates16–20 and
generate human blastocyst-like structures21,22.
The POU factor OCT4, which is expressed across the pluripotency continuum in mouse and human, is considered a fundamental factor for early embryogenesis23–26. OCT4 is the only
factor that is sufﬁcient to trigger reprogramming of mouse and
human somatic cells to induced pluripotent stem cells (iPSCs) in
the absence of other factors27,28. Previous studies of OCT4centered protein–protein interaction networks (i.e., the OCT4
interactomes) in mESCs have identiﬁed important links to transcriptional cofactors, epigenetic modiﬁers, and chromatin remodelers that synergize with OCT4 during mESC self-renewal,
differentiation, and reprogramming29–31. While the genome-wide
targets of OCT4 have been mapped in both mouse and human
ESCs32–35, its physical interactome in hESCs has not to date been
explored. Hence, it remains unclear how OCT4 controls distinct
transcriptional programs in human naïve and primed pluripotent
states.
Here we sought to identify critical OCT4 cofactors in human
pluripotent cells. We captured the dynamic OCT4-centered
protein–protein interaction networks (interactomes) under the
naïve and primed conditions using afﬁnity puriﬁcation followed
by mass spectrometry (AP-MS) and uncovered extensive associations with ATP-dependent chromatin remodelers. Integrative
analysis generated a reference map of stage-speciﬁc transcription
factors (TFs) and chromatin remodelers, linking enhancer reorganization with concordant transcriptional changes. Our work
indicates that a switch in OCT4 partner association contributes to
the activation of distinct target genes in naïve and primed hESCs
and consequently their distinct developmental potential.
Results
Establishing OCT4-centered protein interactomes in naïve and
primed hESCs. To identify OCT4 partners in human pluripotent
cells, we employed transcription activator-like effector nucleases
(TALENs) to target the bacterial ligase BirA to the AAVS1 safe
harbor locus in WIBR2 primed hESCs (Supplementary Fig. 1a–c).
We then targeted a donor vector containing a fusion of the
3xFLAG tag and Biotin recognition sequence (3xFLBio) to the Cterminus of endogenous OCT4 (Fig. 1a, Supplementary Fig. 1d, e,
and see Methods for details). In the presence of BirA this
sequence becomes biotinylated on the lysine residue (Supplementary Fig. 1f), enabling afﬁnity precipitation followed by mass
spectrometry (AP-MS) analysis using streptavidin (SA) beads36.
2

WIBR2-BirA and WIBR2-OCT43xFLBio hESCs retained full
expression of pluripotency genes and differentiation potential
(Supplementary Fig. 1g, h). OCT4-associated proteins were
identiﬁed by SA and 3xFLAG AP-MS under primed conditions
and upon transfer to naïve pluripotency by overexpression of
KLF2 and NANOG transgenes4,5 (Fig. 1a). In addition, we performed native OCT4 antibody pulldown followed by mass spectrometry in WIBR2 and WIBR3 hESCs before and after resetting
using our chemically deﬁned naïve conditions15 (Fig. 1a). Candidate OCT4 partners were selected based on detection in at least
three of four independent MS experiments, removal of background contaminants using the CRAPome37 database, and
spectral count analysis using a combined cumulative probability
(CCP) score38 with a false-discovery rate (FDR) cutoff of 0.1
(Supplementary Fig. 1i, j and Supplementary Data 1). This analysis identiﬁed 30 OCT4-associated proteins in naïve hESCs and
14 in primed hESCs, 9 of which were detected in both pluripotent
states (Fig. 1b). We compared the OCT4 interactome in naïve
hESCs with that in mESCs29–31. Only 7 (23%), 7 (23%), and 13
(43%) proteins were shared between the naïve human OCT4
interactome and three independent mouse studies, respectively
(Fig. 1c). While this limited overlap may hint at species-speciﬁc
differences in OCT4 protein associations, it is important to bear
in mind that the mouse data used in these comparisons were
generated under serum/LIF conditions, which do not truly
represent ground state conditions, but rather a heterogeneous and
metastable state that is intermediate between naïve and primed
pluripotency39. Components of the cohesin complex (SMC1A,
SMCHD1), RNA binding protein L1TD140, DNA mismatch
repair proteins (MSH2, MSH6), and multiple components of
SNF2-family ATP-dependent chromatin remodeling complexes
(Fig. 1c, underlined) were conserved between the mouse and
human OCT4 networks. Interactions of OCT4 with selected
partners in naïve and primed hESCs were validated by coimmunoprecipitation (co-IP) and western blot (Fig. 1d, e). These
results indicate that a subset of OCT4 interaction partners is
conserved between naïve cells in mouse and human.
OCT4-associated SNF2-family ATPases are divergently
expressed in naïve and primed hESCs. The human OCT4
interactome was strongly enriched in components of
mammalian SNF2-family ATP-dependent chromatin remodeling
complexes41–45, including members of the Brahma-associated
factor (BAF or mammalian SWI/SNF) and imitation SWI (ISWI)
complexes (Fig. 2a). The BAF complex contains one of two
mutually exclusive ATPase subunits, BRG1 (SMARCA4) or BRM
(SMARCA2), while other BAF subunits provide structural or
chromatin targeting functions45. BRG1 was detected in both the
naïve and primed OCT4 interactomes, while its paralog ATPase,
BRM was only detected in the naïve OCT4 interactome (Fig. 1b,
Fig. 2a, and Supplementary Fig. 2a). In a similar fashion, ISWI
complexes contain one of two ATPase subunits, SNF2H
(SMARCA5) or SNF2L (SMARCA1), and 2–4 additional
subunits45. SNF2H was detected in both the naïve and primed
OCT4 interactomes, while SNF2L was only detected in the
primed OCT4 interactome (Fig. 1b and Fig. 2a). Hence, OCT4 is
associated with distinct SNF2-family ATPases in naïve and
primed hESCs.
We examined whether these distinct protein interactions may
be explained by differential expression of OCT4 partners. Indeed,
BRM and SNF2L were speciﬁcally expressed in naïve and primed
hESCs, respectively (Fig. 2b, c). Other BAF and ISWI components
were expressed at similar levels in naïve and primed hESCs
(Fig. 2b, c and Supplementary Fig. 2b), although BRG1
was elevated at the protein level in primed cells (Fig. 2b). Similar
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Fig. 1 An OCT4 interactome in human embryonic stem cells (hESCs). a Afﬁnity puriﬁcation mass spectrometry (AP-MS) strategies for identiﬁcation of
OCT4-associated proteins (interactome) in hESCs. Three strategies are used: (i) streptavidin immunoprecipitation (SA-IP) of WIBR2-OCT43xFLBio ESCs or
BirA control; (ii) FLAG-IP of WIBR2-OCT43xFLBio ESCs or BirA control; (iii) native OCT4 and IgG antibody (Ab-IP) pulldown in WIBR2 and WIBR3 hESC
lines. b OCT4-associated proteins identiﬁed in naïve and primed hESCs. Proteins are listed as ofﬁcial gene symbols. c Proteins in the naïve human OCT4
interactome are compared to OCT4-associated proteins identiﬁed in three independent studies in mouse ESCs29–31. Components of SNF2-family
chromatin remodeling complexes are underlined. d OCT4 co-immunoprecipitation (co-IP) followed by western blot of selected OCT4-associated proteins
in naïve and primed hESCs. e BRM (SMARCA2) and BRG1 (SMARCA4) co-IP followed by western blot analysis of BAF155 (SMARCC1) and OCT4. d, e
Experiment is repeated independently twice with similar results.
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Fig. 2 Differential expression of OCT4-associated SNF2-family ATPases in naïve and primed hESCs. a Illustration of naïve-speciﬁc (red/pink), primedspeciﬁc (blue), and common (yellow) components of the mammalian SWI/SNF family of subunits (represented as one complex rather than three
subcomplexes cBAF, PBAF, and ncBAF) and ISWI complexes identiﬁed in the naïve and primed OCT4 interactomes. Pink color indicates proteins that are
identiﬁed with marginal signiﬁcance (0.1 < FDR < 0.2) in the naïve OCT4 interactome. b Western blot analysis of ATPase expression in naïve and primed
hESCs. Experiment is repeated independently twice with similar results. c log2 ratios of mRNA expression of BAF and ISWI components in naïve and primed
hESCs based on a microarray analysis4. d Expression of BRG1 (SMARCA4), BRM (SMARCA2), and SNF2L (SMARCA1) mRNA transcripts in the alternative
t2iLGoY culture condition for naïve human pluripotency (red) and parental primed hESCs (blue) according to RNA-seq data5,46. e log2 ratios of protein
expression of BAF and ISWI components in naïve and primed hESCs based on SILAC followed by MS analysis in two naïve and primed hESC lines. *SNF2L
was quantiﬁed by MS only in WIBR2 cells.

expression patterns were observed in naïve hESCs generated
using t2i/L/Gö, an alternative culture formulation for naïve
hESCs5,46 (Fig. 2d). Some BAF subunits that were identiﬁed in
the naïve OCT4 interactome nonetheless showed an interaction
with OCT4 by co-IP assay in both naïve and primed cells
4

(Supplementary Fig. 2c), suggesting that the stringent cutoffs used
in our AP-MS analysis may have caused some bona ﬁde
interactions to be omitted. Similarly, the topoisomerase TOP2A,
which synergizes with the BAF complex to recruit pluripotency
factors in mouse ESCs47, was identiﬁed in the naïve OCT4
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interactome but its CCP score was only slightly below the cutoff
for inclusion in the primed OCT4 interactome (Supplementary
Fig. 1j). Conversely, its isoform TOP2B was upregulated in
primed cells and exclusively detected in the primed OCT4
interactome (Supplementary Fig. 1j, k). Co-IP assays indicated
that SNF2L and TOP2B form a direct interaction with BRG1 in
primed hESCs (Supplementary Fig. 2d). These data suggest that
some of the protein associations with OCT4 may be bridged by
third partners, such as BRG1.
To determine whether other OCT4-associated proteins were
differentially expressed between naïve and primed hESCs,
we performed stable isotope labeling with amino acids in cell
culture (SILAC) followed by MS to determine global protein
expression levels (Supplementary Fig. 2e). This analysis conﬁrmed that BRG1 was upregulated at the protein level in primed
hESCs, whereas several naïve-speciﬁc OCT4 partners (BRM,
EPPK1, and NLRP2/7) were highly induced in naïve hESCs
(Fig. 2e and Supplementary Fig. 2f). However, most OCT4associated proteins did not show a signiﬁcant shift in expression
between naïve and primed hESCs. We conclude that cell-typespeciﬁc association with OCT4 can be attributed to differential
protein expression in only a handful of cases, including BRM
(naïve speciﬁc) and SNF2L (primed speciﬁc).
OCT4 and BAF complexes shape the naïve- and primedspeciﬁc chromatin landscapes. To explore the role of the BAF
complexes in regulating naïve versus primed human pluripotency, we performed chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) analysis using antibodies
speciﬁc for BRG1 and BAF155 (SMARCC1, a common scaffold
protein of the BAF complex42) under naïve and primed conditions (ChIP-seq QC metrics in Supplementary Data 2 and source
data provided with this paper). A total of 69,007 BAF (BRG1/
BAF155 merged) peaks were identiﬁed in both states, among
which 26,428 peaks (53.0%, 26,428/49,846 of naïve peaks, or
58.0%, 26,428/45,589 of primed peaks) were shared (Fig. 3a).
Consistent with the known role of BAF complexes in promoting
an accessible chromatin architecture, we observed a high overlap
of BAF peaks with open chromatin regions in naïve and primed
cells, as deﬁned by the assay for transposase-accessible chromatin
followed by sequencing (ATAC-seq)48 (Fig. 3b). BAF peaks
speciﬁc to naïve and primed cells showed higher ATAC intensities in their respective states, as exempliﬁed by genes active in
naïve (TFAP2C) and primed (SALL1) states (Fig. 3c, d).
In line with the physical interaction between OCT4 and the
BAF components, OCT4 peak regions from ChIP-seq35 overlapped substantially (57.9%, 14,659/25,329 in naïve state or
74.1%, 15,839/21,359 in primed state) with BAF peaks (Fig. 3e).
Using a clustering method based on the ChIP-seq intensities of
OCT435 and histone H3 modiﬁcation marks K4me34, K27ac35,
and K27me34 at all BAF peak regions (N = 69,007), we deﬁned 10
discrete BAF-bound clusters with distinct occupancy patterns of
OCT4 and active and repressive histone marks in naïve and
primed hESCs (Fig. 3f, Supplementary Fig. 3a, b, and Supplementary Data 3). Of particular interest for understanding
differential gene regulation, clusters 1, 6, and 8 (C1, C6, C8)
represent naïve-speciﬁc, primed-speciﬁc, and shared enhancers,
respectively, that were enriched in OCT4 and the active histone
mark H3K27ac but lacked the promoter mark H3K4me3 and the
repressive mark H3K27me3. Additionally, clusters 4 and 10 (C4,
C10) represent shared and naïve-speciﬁc active promoters,
respectively, that were enriched in OCT4, H3K27ac, and
H3K4me3, but lacked H3K27me3, while cluster 7 (C7) represents
shared bivalent promoters that were enriched in both H3K4me3
and H3K27me3 (Fig. 3f and Supplementary Fig. 3a, b). As
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expected, annotations of these peak regions agreed with their
predicted activity in naïve vs. primed hESCs based on chromatin
accessibility and expression of the nearest genes (Supplementary
Fig. 3c, d).
By examining the presence of TF binding motifs, we identiﬁed
enrichment of TFAP2A/C and KLF4/5 motifs at naïve-speciﬁc
OCT4/BAF-bound enhancers (C1) and promoters (C10) (Fig. 3g
and Supplementary Fig. 3e). KLF4 and TFAP2C were previously
shown to activate enhancers speciﬁc to naïve hESCs14,48. In
contrast, primed-speciﬁc OCT4/BAF-bound enhancers (C6) were
enriched in motifs associated with ZIC2/3 and SOX2/3 (Fig. 3g).
Zic2/3 have been implicated as transcriptional determinants of
primed mouse EpiSCs49,50, while SOX2 is a master regulator of
pluripotent
cells
that
also
contributes
to
neural
differentiation51,52. These ﬁndings suggest that the BAF complex
is recruited to discrete sets of target genes in naïve and primed
hESCs through association with TFs that are differentially
expressed in these two pluripotent states.
To determine the in vivo relevance of these OCT4/BAF-bound
enhancers, we examined stage-speciﬁc enhancers that were
identiﬁed in early human embryos using ATAC-seq analysis53.
Distal ATAC-seq peaks that were identiﬁed speciﬁcally in human
8-cell embryos, ICM, and primed hESCs were compared to naïvespeciﬁc (C1), primed-speciﬁc (C6), and naïve/primed-shared
(C8) enhancer regions. C1 regions were associated with 8-cell
and ICM-speciﬁc ATAC peaks, while C8 regions were only
associated with ICM-speciﬁc ATAC peaks in vivo (Fig. 3h, i).
These data conﬁrm the biological relevance of the identiﬁed
OCT4/BAF-bound enhancers and demonstrate that naïve hESCs
partially recapitulate enhancer signatures of human 8-cell-to-ICM
embryos10.
Naïve and primed-speciﬁc BAF-bound enhancers harbor distinct chromatin remodelers and TFs. Our OCT4 interactome
studies identiﬁed BRM as a naïve-speciﬁc partner (Fig. 1b). ChIPseq analysis identiﬁed 17,413 BRM peaks in naïve hESCs, most of
which (88.8%, 15,463/17,413) were shared with BAF (BRG1/
BAF155) peaks in naïve cells (Supplementary Fig. 4a). Previous
studies suggested that the BRM- and BRG1-containing BAF
complexes are mutually exclusive54,55. In naïve hESCs, we
detected an interaction between these two ATPases by reciprocal
co-IP experiments (Supplementary Fig. 4b). However, the interaction of BRM with BRG1, but not other BAF components
(BAF53A, BAF47), was abolished using a more stringent co-IP
condition (Supplementary Fig. 4c). Hence, the two ATPases are
likely not assembled in the same BAF complex, which is consistent with structural studies42,56, and their association in naïve
hESCs may be bridged by a third interactor, such as OCT4.
The enrichment of the KLF4 motif at naïve-speciﬁc (C1)
enhancers and of the SOX2 motif at primed-speciﬁc (C6)
enhancers (Fig. 3g) prompted us to further investigate the
genome-wide location of KLF4 and SOX2 in naïve and primed
hESCs by CUT&Tag and ChIP-seq analysis, respectively
(Supplementary Data 2). Interestingly, expression of KLF4 and
SOX2 was largely naïve and primed speciﬁc, respectively
(Supplementary Fig. 4d, e). Accordingly, association of KLF4 to
chromatin was only detected in naïve hESCs, while that of SOX2
was detected with a much larger proportion in primed than naive
hESCs (Fig. 4a and Supplementary Fig. 4f). In naïve hESCs, BRM
and KLF4 were enriched at naïve speciﬁc and common BAF
(BRG1/BAF155) peaks, while SOX2 occupied all BAF peaks with
a low intensity. In contrast, SOX2 was more enriched at primed
speciﬁc and common BAF regions in primed hESCs (Fig. 4b).
These data suggest that SOX2 may function as a largely primedspeciﬁc TF in the human context, although its genome-wide
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binding in naïve hESCs was still weakly correlated with that of
OCT4 (Fig. 4c). We then examined the association of statespeciﬁc chromatin remodelers and TFs with BAF-bound
enhancers. BRG1, BRM, KLF4, OCT4, and TFAP2C48 were
enriched at naïve-speciﬁc (C1) and naïve/primed-shared (C8)
enhancers, while BRG1, SOX2, and OCT4 were enriched at
primed-speciﬁc (C6) and naïve/primed-shared (C8) enhancers
(Fig. 4d and Supplementary Fig. 4g). Thus, the naïve and primedspeciﬁc enhancers harbor distinct ATP-dependent chromatin
remodelers and TFs (Fig. 4e).
To investigate whether such a switch in OCT4 partner
association could also be observed in transcriptome studies of
human embryos, we analyzed single-cell RNA-seq (scRNA-seq)
data from human embryos between days 6 and 14 of
development57. By proﬁling cells corresponding to the epiblast
(EPI) lineage over this period, we observed elevated expression of
the naïve-associated factors BRM, KLF4, and TFAP2C during
early timepoints, which diminished after day 9 (Fig. 4f). The
primed-speciﬁc OCT4 partner SNF2L was induced starting at day
9 together with SOX2 and subsequently, ZIC2. In contrast, OCT4,
BRG1, and SNF2H maintained a relatively constant expression
level over this time course (Fig. 4f). These transcriptional
dynamics are consistent with the dynamic reorganization of
OCT4 protein partners observed in naïve and primed hESCs
in vitro.
Naïve- and primed-speciﬁc BAF-bound enhancers drive
expression of blastocyst and ectodermal signatures, respectively.
We examined the identity of the target genes of the OCT4/BAFbound enhancers in naïve and primed hESCs. Naïve-speciﬁc
OCT4/BAF-bound enhancers (C1) were located nearby genes that
are involved in blastocyst development, blastocyst formation, and
trophectoderm differentiation. Examples of such genes include
NLRP7, TEAD4, and TFAP2C (Fig. 5a–c). In contrast, primedspeciﬁc OCT4/BAF-bound enhancers (C6) were located nearby
genes that are involved in differentiation towards ectoderm
(Fig. 5d), which is consistent with recent evidence in the mouse
that ectodermal enhancers become primed in the early postimplantation epiblast58. Examples of such genes include SALL1,
PTPRZ1, and ZIC3 (Fig. 5e, f). As expected, naïve/primed-shared
OCT4/BAF-bound enhancers (C8) were located nearby genes that
are involved in stem cell population maintenance (Supplementary
Fig. 5a, b). Comparison with scRNA-seq data from human
embryos57 conﬁrmed that naïve-speciﬁc enhancer target genes
(C1) were more highly expressed during early timepoints, whereas
primed-speciﬁc enhancer target genes (C6) were more highly
expressed after day 9 (Fig. 5g and Supplementary Data 3). Similar
expression dynamics were observed in non-human primate
embryos59 (Supplementary Fig. 5c). In accordance with prior
studies that examined the developmental identity of naïve
hESCs46,60, naïve hESCs displayed a human ICM-speciﬁc
gene expression signature53 (Fig. 5h), which was conﬁrmed by
principle component analysis (PCA) (Fig. 5i). These data indicate
that OCT4/BAF-bound enhancers drive the expression of
blastocyst-speciﬁc genes in naïve hESCs.
Since the primed-speciﬁc OCT4/BAF-bound enhancers (C6)
were associated with genes involved in ectoderm development, we
investigated the activity of these enhancers in human neural
progenitor cells (hNPCs). Primed-speciﬁc OCT4/BAF-bound
enhancers overlapped substantially with SOX2 peaks in hNPCs52
(Fig. 5j, k). Chromatin accessibility, BRG1 binding, and the
enhancer-associated histone marks H3K27ac and H3K4me1 were
all highly enriched at primed-speciﬁc enhancers (C6) compared
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to naïve-speciﬁc enhancers (C1) in hNPCs54 (Fig. 5l and
Supplementary Fig. 5e). In line with activity of these enhancers,
expression of primed-speciﬁc enhancer target genes was signiﬁcantly higher in primed hESCs and hNPCs compared to naïve
hESCs (Supplementary Fig. 5d). In addition, we putatively
identiﬁed a naïve-speciﬁc (C1, distance to TSS: 50 kb) and a
primed-speciﬁc (C6, distance to TSS: 45 kb) enhancer within
downstream intergenic regions of SOX2. BRG1 and OCT4 cooccupied the C1 enhancer in naïve hESCs, whereas BRG1 and
OCT4/SOX2 co-occupied the C6 enhancer in primed hESCs, and
ﬁnally BRG1 and SOX2 remained present at the C6 enhancer in
hNPCs (Supplementary Fig. 5f). These data reveal a regulatory
cascade at distinct enhancers controlled by stage-speciﬁc TFs and
BAF chromatin remodelers to drive expression of SOX2 in hESCs
and hNPCs.
Functional redundancy of BRG1 and BRM in naïve hESCs. We
examined the functional signiﬁcance of the BAF complex in
controlling naïve and primed human pluripotency. We performed short hairpin RNA (shRNA)-mediated knockdown (KD)
of BRG1 in naïve and primed hESCs, and KD of BRM in naïve
hESCs (Fig. 6a). Knockdown resulted in more than 50% reduction in mRNA transcript and protein levels of each target gene
(Supplementary Fig. 6a, b). Approximately two hundred genes
(101 Down, 94 Up, fold change > 2, p value < 0.05) were differentially expressed upon BRG1 KD in primed hESCs, but little
effect was seen in naïve hESCs upon depletion of either BAF
ATPase (Fig. 6b and Supplementary Data 4). In agreement with
prior ﬁndings61, BRG1 knockdown in primed hESCs caused
upregulation of genes with bivalent chromatin domains, as
identiﬁed in C7 of our clustering analysis (Fig. 3f and Supplementary Fig. 3b). In particular, regulators of endodermal lineage
differentiation, such as SOX17, GATA4, FOXA2, and LGR5, were
signiﬁcantly upregulated in response to BRG1 depletion in
primed hESCs (Fig. 6b and Supplementary Fig. 6c–e).
Since KD of neither ATPase had a signiﬁcant effect on
transcription in naïve hESCs, we examined whether BRG1 and
BRM may have an overlapping functional role in naïve human
pluripotency. We ﬁrst introduced guide RNA (gRNAs) targeting
the ATPase domains of BRG1 or BRM into primed hESCs and
genotyped individual clones (Fig. 6c). One third of clones
nucleofected with BRG1 gRNAs contained heterozygous frameshift mutations in BRG1, but none contained homozygous
frameshift mutations (Fig. 6d). In contrast, nucleofection with
BRM gRNAs generated equivalent proportions of clones that
were wild-type (WT), heterozygous (HET), or knockout (KO) for
BRM (Fig. 6d). These results conﬁrm that BRG1, but not BRM, is
critical for self-renewal of primed hESCs. We then reprogrammed
these primed BRM+/+, BRM+/−, or BRM−/− hESCs to the naïve
state and found that cells of all three genotypes expressed the
naïve cell-surface markers CD75 and SUSD262,63, although CD75
intensity was marginally reduced in the absence of BRM (Fig. 6e, f
and Supplementary Fig. 6f). Western blot analysis indicated that
BRG1 protein levels increased in the absence of BRM, suggesting
a potential compensatory mechanism (Fig. 6g). We then
attempted to deplete BRG1 in naïve hESCs that were also
deﬁcient in BRM. gRNAs targeting the ATPase domain of BRG1
were introduced into WT and two independent clones of
BRM−/− naïve hESCs. The frequency of insertion–deletions
(indels) in each genetic background was determined by sequencing. While we detected a substantial (43.4%) frequency of BRG1
alleles containing indels in WT naïve cells, very few (<9%) BRG1
indels were detected in the BRM−/− background (Fig. 6h). In
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addition, KD of BRG1 in BRM−/− naïve cells resulted in severe
collapse of colony morphology and loss of the CD75+/SUSD2+
population compared to KD of BRG1 in WT naïve cells (Fig. 6i).
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ATPases are selectively eliminated during culture.
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containing homozygous mutations in the BRG1 ATPase domain
(Fig. 7a). These cells lacked detectable BRG1 protein expression
(Fig. 7b) but maintained expression of CD75 and SUSD2 (Fig. 7c).
Furthermore, RNA-seq analysis indicated few differentially
expressed genes (DEGs) between WT, BRM−/−, and BRG1−/−
naïve hESCs (Supplementary Fig. 7a). We surmise that neither
BRM nor BRG1 is required for maintenance of naïve hESCs,
which supports our hypothesis that these two ATPases play a
functionally redundant role in naïve human pluripotency.
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Fig. 5 Naïve and primed-speciﬁc enhancers drive expression of blastocyst and ectodermal lineage signatures, respectively. a–c Gene ontology (GO)
analysis (a), ChIP-seq tracks (b), and expression from RNA-seq analysis (c) of representative target genes (NLRP7, TEAD4, and TFAP2C) located nearby
naïve-speciﬁc OCT4/BAF-bound enhancers (C1). d–f GO analysis (d), ChIP-seq tracks (e), and expression from RNA-seq analysis (f) of typical target
genes (SALL1, PTPRZ1, and ZIC3) located nearby primed-speciﬁc OCT4/BAF-bound enhancers (C6). a, d P value is from the right-sided Fisher’s Extract test.
c, f Data are presented as mean ± SD, obtained from n = 2 biologically independent experiments. g Expression of C1 and C6 target genes in a scRNA-seq
analysis of epiblast cells in human embryos cultured in a 3D matrix between days 6 and 14 of development57. Boxplot presents the 25th, median, and 75th
quartiles, and the whiskers extend 1.5 of interquartile ranges. h Geneset Enrichment Analysis (GSEA) for the terms “ICM-signature” and “Primed hESCsignature” in naïve versus primed hESCs used in this study. These signature genes were deﬁned in a transcriptome study of human preimplantation
embryos53. i Principal component analysis (PCA) of RNA-seq data from naïve and primed hESCs (this study) and distinct stages of human preimplantation
development53. j Overlap of SOX2 peaks in human neural progenitor cells (hNPC)52 and primed-speciﬁc enhancer (C6) regions in hESCs. P value is from
the right-sided Fisher’s Extract test. k Heatmaps and intensity plots of SOX2 ChIP-seq in hNPCs52 at naïve- (C1) and primed-speciﬁc (C6) enhancer
regions. l Intensity plots of ATAC-seq, BRG1, and enhancer marks H3K27ac and H3K4me1 in hNPCs54 at naïve- (C1) and primed-speciﬁc (C6) enhancer
regions.

BRG1 regulates chromatin accessibility during the exit from
naïve pluripotency. Since we were unable to derive BRG1−/−
primed hESCs (Fig. 6d), we hypothesized that BRG1 is essential
for establishment of primed pluripotency. Naïve hESCs containing different BRG1 genotypes were treated with primed media, a
process called “re-priming” (Fig. 7d). WT and BRG1+/− naïve
hESCs rapidly acquired a ﬂattened epithelioid morphology typical
of primed hESCs within 5 days of repriming. In contrast,
BRG1−/− naïve hESCs initially retained a dome-shaped colony
morphology (Fig. 7d). In agreement with this delayed morphological transition, WT and BRG1+/− naïve hESCs showed more
rapid induction of the primed-speciﬁc cell-surface marker CD90
(Fig. 7e). ATAC-seq analysis revealed few differentially accessible
regions (DARs, FDR < 0.05) between WT, BRG1+/−, or BRG1−/−
cells under naïve conditions (Fig. 7f). In contrast, chromatin
accessibility was substantially reduced (3940 out of 3945, or
99.9% DARs) in BRG1−/− cells compared to WT/BRG1+/− cells
during repriming (Fig. 7f). These reduced DARs (N = 3940) were
enriched in the primed speciﬁc (C6) and naïve/primed-shared
(C8) OCT4/BAF-bound enhancers identiﬁed in our ChIP-seq
analysis (Fig. 7g and Supplementary Fig. 7b). The C6 enhancers
with reduced chromatin accessibility were associated with target
genes that are upregulated in both primed hESCs and hNPCs
(Supplementary Fig. 7c). Hence, the removal of BRG1 alters the
epigenomic landscape during the naïve-to-primed transition
(Fig. 7h and Supplementary Fig. 7d).
Finally, we performed RNA-seq analysis on WT, BRG1+/−,
and BRG1−/− hESCs during 5 days of repriming. BRM transcript
was rapidly downregulated, while BRG1 levels were maintained
in WT cells (Supplementary Fig. 7e). There were 1897 and 2064
DEGs signiﬁcantly (fold change > 2, p value < 0.05) upregulated
in WT naïve and primed cells, respectively (Fig. 7i and
Supplementary Data 5). Clustering analysis based on these
DEGs indicated that cells undergoing repriming acquired an
intermediate transcriptional identity (Supplementary Fig. 7f).
499 (out of 1897, 26.3%) and 573 (out of 2064, 27.8%) of these
DEGs were signiﬁcantly down and upregulated, respectively,
during repriming compared with the naïve state (Fig. 7i).
Consistent with the retention of a naïve colony morphology, the
reduction of naïve-speciﬁc genes and activation of primedspeciﬁc genes were delayed in BRG1−/− cells (Fig. 7j and
Supplementary Fig. 7g). Examples of genes showing delayed
repriming kinetics in BRG1−/− cells include the naïve-speciﬁc
TF DPPA3 and the primed-speciﬁc genes GAP43, ROR1, and
ZIC3, which also exhibited reduced chromatin accessibility at
enhancer and/or promoter regions (Fig. 7k–m and Supplementary Fig. 7h). Hence, while BRG1 appears to be dispensable for
maintenance of naïve hESCs, it plays a critical role in ensuring
adequate chromatin accessibility during the exit from naïve
pluripotency.
10

Discussion
In summary, we have generated an interactome of protein–protein
interactions around OCT4 in primed hESCs and then reconstructed this interactome under recently devised conditions for
naïve human pluripotency. Our results indicate that OCT4
engages in dynamic interactions with ATP-dependent chromatin
remodelers in human pluripotent states. While the interaction
between OCT4 and BRG1 has been well documented in mouse
ESCs44,64, its association with distinct chromatin remodelers
under naïve and primed conditions was not previously reported.
The currently prevailing view is that BRG1 is the key catalytic
subunit of BAF complexes in ESCs64 and early embryos65,66,
whereas BRM is thought to play a greater role in differentiated
cells that are less proliferative67. By assessing the expression,
genome-wide binding, and function of BAF subunits in naïve and
primed hESCs, we propose that both BRG1 and BRM contribute
to the activation of enhancers involved in blastocyst development
and trophectoderm speciﬁcation in naïve cells. Co-binding of
KLF4 and TFAP2C to OCT4/BAF-bound enhancers suggests that
these two TFs provide speciﬁcity to OCT4 binding in the naïve
state, as was previously reported for KLF4 during the early stages
of human ﬁbroblast reprogramming14. In contrast, OCT4 engages
with the BRG1-containing BAF complex and SOX2 to activate
ectodermal enhancers in primed hESCs. This precocious activation of ectodermal enhancers in primed hESCs is consistent with
recent evidence from mouse embryos that ectodermal enhancers
become primed in the early post-implantation epiblast58. Thus,
our interactome analysis has uncovered a switch in OCT4 protein
partners that orchestrates a dynamic reconﬁguration of the
enhancer landscape during the interconversion between naïve and
primed pluripotent states (Fig. 8). This remodeling of the epigenetic landscape may explain the distinct developmental competencies of naïve and primed hESCs towards trophoblast and neural
fates, respectively17.
The temporal expression dynamics of OCT4-associated factors
between days 6 and 14 of human embryonic development recapitulate the expression changes observed during the naïve-toprimed transition in hESCs. While BRM and KLF4 are activated
in the preimplantation epiblast, SOX2 is most signiﬁcantly
induced at later stages. Indeed, our ChIP-seq data suggest that
SOX2 functions largely as a primed-speciﬁc TF in the human
context, in contrast to its central role in naïve mouse ESCs68.
Whether BRM also plays a previously underappreciated role in
mouse ESCs and early embryogenesis will require future investigation. However, blastocyst outgrowths from double heterozygous intercrosses indicated a combined gene dosage
requirement for Brg1 and Brm during mouse peri-implantation
development69. Such functional redundancy may provide a failsafe mechanism to ensure adequate chromatin accessibility at the
blastocyst stage before BRM expression is extinguished and BAF
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catalytic activity becomes exclusively reliant on BRG1 in the postimplantation epiblast. This transition is modelled during the
naïve-to-primed transition in vitro, which we have shown here is
critically dependent on BRG1 to promote adequate chromatin
accessibility at primed-speciﬁc enhancers and promoters. We
propose that BRM and BRG1 have overlapping functions in naïve
hESCs, but not during later stages of development. This would
explain why many human diseases are caused by haploinsufﬁciency of BAF subunits41. Consistent with this interpretation,

Brm was required to prevent implantation defects but not neural
tube defects in Brg1 heterozygous mice69.
An important focus for future studies will be to identify
functional enhancers that are activated by the BAF complex
during the primed-to-naïve transition. Since BRG1 is essential for
the self-renewal of primed cells, such experiments will likely
require the use of inducible systems to deplete one or both catalytic subunits of the BAF complex at discrete stages of resetting.
In addition, the OCT4 interactome data in this study provide a
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Fig. 6 Functional redundancy of BRG1 and BRM in naïve hESCs. a Schematic depicting the generation of BRM or BRG1 knockdown (KD) in both naïve (red)
and primed (blue) hESCs. b Volcano plots of signiﬁcantly dysregulated genes (fold change > 2, p value < 0.05, from unpaired two-sided t-test) in shBRM vs.
control KD in naïve hESCs, shBRG1 vs. control KD in naïve hESCs, and shBRG1 vs. control KD in primed hESCs. c Schematic depicting the generation of BRM
or BRG1 knockout (KO) clones by CRISPR/Cas9 targeting of each ATPase in primed hESCs. d Genotypes of primed hESC lines obtained after CRISPR
targeting of BRM (n = 52 clones) or BRG1 (n = 24 clones) ATPase domain. Note that we were unable to derive primed hESC lines containing homozygous
frameshift mutations in BRG1. e Phase contrast images of cell lines analyzed in primed hESCs and naïve hESCs with three distinct BRM genotypes: wild-type
(BRM+/+), heterozygous (BRM+/−), or homozygous (BRM−/−). Scale bar is 200 μm. f Flow cytometry analysis for the naïve cell-surface markers CD75
and SUSD2 in the previous panel. n = 3 independent BRG1 KO clones were analyzed. g Western blot analysis for BRM, BRG1, OCT4, and GAPDH in BRM
WT, HET, and KO (three independent clones) naïve hESCs. h Frequency of BRG1 insertion–deletions (indels) after introduction of sgRNAs targeting the
BRG1 ATPase domain in WT naïve hESCs and two independent BRM KO clones. Numbers of reads sequenced in each cell line are indicated at the top of the
histogram. i BRG1 KD in BRM−/− naïve hESCs impairs self-renewal as assessed by morphological changes and reduced expression of the naïve cell-surface
markers CD75 and SUSD2. This experiment is representative of n = 2 biological replicates. Scale bar is 200 μm.

rich resource to explore other candidate regulators of human
pluripotency. For example, it will be instructive to determine how
ISWI complexes (containing SNF2H or SNF2L as ATPases)
contribute to epigenetic remodeling in human pluripotent cells.
Intriguingly, Snf2h−/− mouse embryos die during the periimplantation stage, which has been attributed to growth arrest in
both ICM and trophectoderm lineages70. Furthermore, evidence
from mouse ESCs indicates that SNF2H, but not BRG1, plays a
dominant role in orchestrating chromosome folding and insulation of topologically associated domains43. Other candidates of
interest include the chromatin remodeler BEND371 and the RNA
binding protein NLRP78, both of which are naïve-speciﬁc OCT4
partners. Taking a cue from multiple studies in the mouse system
over the past decade, we propose that elucidating the role of
OCT4-associated proteins in human stem cells will likely yield
important insights into the molecular basis of pluripotency, differentiation, and reprogramming.
Methods
Cell culture
Primed hESC culture. WIBR2 and WIBR3 primed hESCs were maintained on
mitomycin C-inactivated mouse embryonic ﬁbroblast (MEF) feeder layers in
primed hESC medium (hESM) and passaged using Collagenase IV (Gibco,
1.5 mg/mL), as previously described4,72,73. Primed hESC medium consisted of
DMEM/F12 supplemented with 15% fetal bovine serum, 5% KnockOut Serum
Replacement, 1 mM GlutaMax (Gibco, 35050), 1% nonessential amino acids
(Gibco, 11140), 1% penicillin-streptomycin (Gibco, 15140), 0.1 mM βmercaptoethanol and 4–8 ng/ml FGF2. H9 primed hESCs were cultured in mTeSR
Plus (STEMCELL Technologies, 05825) on Matrigel hESC-Qualiﬁed Matrix
(Corning, 354277) coated wells and passaged using Gentle Cell Dissociation
Reagent (STEMCELL Technologies, 07174) every 4 to 6 days.
Primed-to-naïve resetting. Chemically induced resetting of primed hESCs to naïve
pluripotency was performed as previously described4,15. 2 × 105 single primed cells
were seeded on a six-well plate with MEF feeder layer in 2 mL primed hESC
medium (for WIBR2/3) or mTeSR1 (for H9) supplemented with 10 μM Y-27632
(Stemgent, 04-0012). Two days later, medium was switched to 5i/L/A naïve media
(see below for details). Ten days after seeding, the cells were expanded polyclonally
using Accutase (Gibco, A1110501) or TrypLE Express (Gibco, 12604) on a MEF
feeder layer. Media were changed every 1–2 days. For AP-MS experiments, we also
performed transgene-mediated resetting to naïve pluripotency as previously
described4. WIBR2-BirA and WIBR2-OCT43xFLBio human ESCs were infected with
Doxycycline (Dox)-inducible KLF2 and NANOG lentiviral transgenes and maintained in 1 μM PD0325901 (Stemgent, 04-0006), 1 μM CHIR99021 (Stemgent, 040004), 20 ng/ml hLIF (Peprotech, 300-05), 2 µg/ml DOX, and 10 μM ROCK
inhibitor Y-27632 (2i/L/DOX+RI).
Naïve hESC culture. Naive hESCs were cultured on mitomycin C-inactivated MEF
feeder cells and were passaged by a brief PBS wash followed by single-cell dissociation using 5 min treatment with Accutase or TrypLE Express (Gibco, 12604)
and centrifugation in ﬁbroblast medium [DMEM (Millipore Sigma, #SLM-021-B)
supplemented with 10% FBS (Millipore Sigma, ES-009-B), 1× GlutaMAX, and 1%
penicillin-streptomycin]. Naïve hESCs were cultured in 5i/L/A media as previously
described4. Five hundred milliliters of 5i/L/A was generated by combining: 240 mL
DMEM/F12 (Gibco, 11320), 240 mL Neurobasal (Gibco, 21103), 5 mL N2 100×
supplement (Gibco, 17502), 10 mL B27 50× supplement (Gibco, 17504), 1× GlutaMAX, 1× MEM NEAA (Gibco, 11140), 0.1 mM β-mercaptoethanol (Millipore
Sigma, 8.05740), 1% penicillin-streptomycin, 50 µg/ml BSA Fraction V (Gibco,
12

15260), and the following small molecules and cytokines: 1 μM PD0325901
(Stemgent, 04-0006), 1 μM IM-12 (Enzo, BML-WN102), 0.5 μM SB590885 (Tocris,
2650), 1 μM WH4-023 (A Chemtek, H620061), 10 μM Y-27632 (Stemgent, 040012), 20 ng/mL hLIF (Peprotech, 300-05), and 10 ng/mL Activin A (Peprotech,
120-14). For MS experiments, the GSK3 inhibitor IM-12 was omitted from the 5i/
L/A cocktail to achieve enhanced proliferation (4i/L/A), as previously described15.
BRM-targeted and BRG1-targeted naïve hESCs were transferred from 5i/L/A to
PXGL74 since this maintenance medium better supported clonal expansion following CRISPR/Cas9-mediated genome editing. PXGL media consisted of
N2B27 supplemented with 1 μM PD0325901, 2 μM XAV939 (Selleckchem, S1180),
2 μM Gö6983 (Tocris, 2285), and 20 ng/mL human LIF. 10 μM Y-27632 was added
during passaging. All naïve hESC experiments were conducted in 5% O2, 5% CO2.
SILAC labeling. To perform quantitative mass spectrometry based whole-proteome
comparison of primed and naive pluripotent states, WIBR2 and WIBR3 primed
hESCs were cultured in SILAC heavy medium whereas chemically reset naïve
hESCs were cultured in 4i/L/A naïve medium (SILAC light). For the SILAC heavy
condition, primed hESCs were grown for three passages in DMEM/F12 with
corresponding complete supplements but deﬁcient in both L-lysine and L-arginine
and supplemented with heavy 13C615N4 L-arginine and 13C615N2 L-lysine (Cambridge Isotope Laboratories). The medium was supplemented with 10% dialyzed
FBS for SILAC (Thermo Fisher Scientiﬁc), and all other gradients followed the
normal condition for primed hESC culture.
Repriming of naïve hESCs. The naïve-to-primed pluripotency transition (repriming) was performed as previously described75. Naïve hESCs were single cell dissociated using TrypLE Express and 5 × 105 cells were seeded per Matrigel-coated
well in mTeSR Plus supplemented with 10 µM Y-27632. The cells were cultured in
5% CO2 and 20% O2. After 2 days, Y-27632 was withdrawn and cells were collected
on d5 for RNA-seq analysis. To improve survival and sample quality for ATAC-seq
analysis, the repriming protocol was modiﬁed by seeding naïve hESCs on a MEF
feeder layer and cells were harvested 4 days after transfer to mTeSR Plus media.
Donor vectors for gene targeting in hESCs. AAVS1 and OCT4 TALEN plasmids
were designed and assembled as previously described72. Intron 1 of the AAVS1
locus was targeted to constitutively express biotin ligase BirA. The OCT4 loci were
targeted to express the 3xFLAG sequence followed by a 23 amino acid recognition
for biotin ligase BirA, which becomes biotinylated on the lysine residue. Donor
vectors were constructed by PCR amplifying homology arms from the corresponding loci using genomic DNA isolated from hESCs. The homology arms
followed by either biotin ligase of E. coli BirA or 3xFLAG-Biotin sequences were
cloned into pCR2.1-TOPO vector (Invitrogen) using standard cloning methods.
TALEN-mediated gene targeting in hESCs. To target the CAGGS-BirA-V5His
sequence to the AAVS1 locus, WIBR2 human ESCs were cultured with ROCK
inhibitor (10 µM) 24 h prior to electroporation. Cells were harvested using 0.25%
trypsin/EDTA solution (Invitrogen) and resuspended in phosphate buffered saline
(PBS). Ten million cells were electroporated with 40 μg of donor vector and 5 μg of
each AAVS1 TALEN encoding plasmid (Gene Pulser Xcell System, Bio-Rad: 250 V,
500 μF, 0.4 cm cuvettes). Cells were subsequently plated on DR4 MEFs feeder layer
with neomycin for selection in hESCs medium supplemented with 10 μM ROCK
inhibitor (Y-27632) for the ﬁrst 24 h. Individual colonies were picked and
expanded after neomycin selection (300 μg/ml) 10–14 days after electroporation.
Gene targeting analysis was veriﬁed by Southern blotting (EcoRV digested). To
introduce a 3xFLAG-Biotin sequence at the C-terminus of endogenous OCT4,
WIBR2-BirA hESCs were used and the same electroporation protocol was applied
with 40 μg of donor vector and 5 μg of each OCT4 TALEN encoding plasmid.
Correctly targeted clones were conﬁrmed by Southern blot analysis (BamHI
digested). Then the PGK-Puro selection cassette was removed by transient
expression of Cre recombinase in WIBR2-OCT43xFLBio-Puro hESCs. Brieﬂy, hESCs
were transfected with 40 μg pTurbo-Cre (GenBank accession number AF334827)
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and 10 μg ﬂuorescent FUW-Tomato vector with the same electroporation protocol.
Two days later, Tomato-expressing cells were FACS-puriﬁed and replated at low
density on MEF feeder layers. Individual colonies were picked and expanded
10–14 days after FACS sorting. The excision of the PGK-puro selection cassette was
conﬁrmed by Southern blot analysis.
Southern blot. Genomic DNA was extracted from WIBR2, WIBR2-BirA, and
WIBR2-OCT43xFLBio hESCs (before and after Cre excision of the PGK-Puro
selection cassette) by tail lysis buffer (10 mM Tris-Cl (pH8.0), 100 mM NaCl,
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10 mM EDTA, 0.5% SDS and 0.4 mg/ml proteinase K) and incubated overnight at
37 °C. The next morning an equal volume of isopropyl alcohol was added and
centrifuged at 6000 × g for 5 min. The supernatant was discarded, and the pellet
resuspended in 1 ml of 70% ethanol for washing and centrifuged at 6000 × g for
5 min. At this point the supernatant was carefully decanted and the pellet air dried
before being resuspended in 200 μl TE buffer. Five micrograms aliquots were
digested overnight with the appropriate enzymes (EcoRV for AAVS1 targeting,
BamHI for OCT4 targeting) at 37 °C. Digested genomic DNA was separated on a
0.8% agarose gel followed by capillary transfer to a Hybond N+ membrane
(Amersham Biosciences). For making an AAVS1-speciﬁc internal probe, the donor
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Fig. 7 BRG1 regulates chromatin accessibility during the exit from naïve pluripotency. a Schematic overview of CRISPR/Cas9-mediated generation of
BRG1 KO naïve hESCs and representative images. n = 3 independent BRG1 KO clones were generated. Scale bar is 200 μm. b Western blot analysis for
BRG1, BRM, NANOG, and ACTIN in WT (BRG1+/+), HET (BRG1+/−), and KO (BRG1−/−) naïve hESCs (three independent clones). c Flow cytometry
analysis for the naïve cell-surface markers CD75 and SUSD2 in primed hESCs and naïve BRG1 KO hESCs. n = 3 independent BRG1 KO clones were analyzed.
d Schematic overview of the naïve-to-primed pluripotency transition and representative images with WT, BRG1+/−, and BRG1−/− cells on day 5 of
repriming. Scale bar is 200 μm. e Histogram representing the mean ﬂuorescence intensity (MFI) of CD90 cell-surface antibody staining in BRG1 WT, HET,
and KO cells on d10 of repriming compared to naïve and primed hESCs. n = 3 independent BRG1 KO clones were analyzed. f Scatterplots showing the
distribution of ATAC-seq peaks in BRG1 KO vs. WT/HET cells under naïve conditions (top) or on day 4 of repriming (bottom). Sites with signiﬁcantly
different ATAC intensities were determined by FDR < 0.05. g Mean ATAC-seq intensity at primed-speciﬁc (C6) and naïve-primed-shared (C8) enhancers
of the BAF peaks during repriming in BRG1 KO vs. WT/HET cells. h Principal component analysis (PCA) of ATAC-seq proﬁles from BRG1 WT, HET, and KO
cells under naïve conditions and during repriming compared to published ATAC-seq data of naïve and primed hESCs48,53. i Volcano plot (left) showing
differentially expressed genes (fold change > 2, p value < 0.05, from unpaired two-sided t-test) between naïve and primed (WT) hESCs. Pie charts (right)
for portions of naïve genes with decreased expression and primed genes with increased expression on day 5 repriming, compared with day 0 of naive cells.
j Expression of the subsets of naïve genes decreased in repriming (left) and primed genes increased in repriming (right) from RNA-seq analysis of BRG1
WT/HET and KO cells under naïve, primed conditions, and during repriming. i, j Data are obtained from n = 3 biologically independent experiments. k
Volcano plot showing differentially expressed genes between BRG1 KO and WT/HET naïve hESCs on day 5 of repriming. l Expression of BRG1-activated (N
= 87) and -repressed (N = 99) genes on day 5 of repriming in naïve and primed hESCs. m RNA-seq and ATAC-seq tracks at the ZIC3 locus showing
reduced expression and chromatin accessibility at enhancer and promoter regions in BRG1−/− cells during repriming. Boxplots (j, l) present the 25th,
median, and 75th quartiles, and the whiskers extend to the 1.5 of interquartile ranges. P value is from two-sided Mann–Whitney test.

in PBS and incubated with the samples overnight at 4 °C. The cells were treated
with an appropriate Molecular Probes Alexa Fluor® dye conjugated secondary
antibodies (Donkey-α-Mouse Alexa Fluor® Plus 594 Cat# A32744 and Donkey-αGoat Alexa Fluor® Plus 488 Cat# A32814, both 1:500, Invitrogen) and then
incubated for 1 h. The nuclei were stained with DAPI for 10 min.
Teratoma formation. WIBR2-BirA and WIBR2-OCT43xFLBio hESCs were collected by Collagenase treatment and separated from feeder cells by subsequent
washes with medium and sedimentation by gravity. The cells were resuspended in
250 µl of PBS and injected subcutaneously into SCID mice. Tumors developed
within 4–8 weeks and animals were sacriﬁced before tumor size exceeded 1.5 cm in
diameter. Teratomas were isolated after sacriﬁcing the mice and ﬁxed in formalin.
After sectioning, teratomas were diagnosed based on hematoxylin and eosin
staining.

Fig. 8 Model of enhancer regulation by common (OCT4, BRG1) and statespeciﬁc TFs and chromatin remodelers in naïve and primed hESCs. In
naïve hESCs OCT4 regulates enhancers of blastocyst-speciﬁc and stem cell
maintenance genes together with the BAF ATPases BRG1 and BRM.
Speciﬁcity of OCT4/BAF targeting to these naïve-speciﬁc genomic sites is
conferred by the naïve TFs TFAP2C and KLF4, which are downregulated
during the naïve-to-primed transition in hESCs and in human embryos
cultured through implantation stages in vitro57. In contrast, in primed
hESCs OCT4 and SOX2 control expression of pan-ectodermal lineage and
stem cell maintenance genes together with the BAF ATPase BRG1. Hence,
the BAF complex has overlapping and divergent roles in naïve and primed
pluripotent states in human.
vector was digested with SacI and EcoRI enzyms to generate a 643 bp fragment of
5′ arm of AAVS1. External probes speciﬁc to OCT4 were ampliﬁed from genomic
DNA outside the region of the targeting arms. These DNA fragments were labeled
by using [∝-32P] dCTP and Prime-It II Random Primer Labeling Kit (Agilent
Technologies) according to the manufacturer’s protocol. Hybridization was carried
out overnight at 65 °C. Post-hybridization washes were done sequentially with two
standard saline citrate (SSC) solutions (20× SSC; 3 M NaCl in 0.3 M sodium citrate
(pH 7.0)), 2× SSC, and 0.2× SSC along with 0.2% SDS, each for 20 min at 65 °C.
Blots were exposed at −80 °C with X-ray ﬁlm in ﬁlm cassette for 24 h. Finally, the
ﬁlms were developed by an auto-processor in a darkroom.
Immunostaining. Cells in 12-well plates were ﬁxed in PBS supplemented with 4%
paraformaldehyde for 20 min at room temperature. The cells were then permeabilized and blocked using 0.2% Triton X-100, 0.1% Tween-20 and 3% donkey
serum in PBS for 30 min. Primary antibody against human OCT4 (1:500, Santa
Cruz, sc-5279), human SOX2 (1:500, R&D Systems, AF2018), and human NANOG
(1:250, goat polyclonal, R&D Systems, AF1997) was diluted in 0.2% Triton X-100
14

Afﬁnity puriﬁcation of OCT4-associated protein complexes. To identify
OCT4-associated proteins in primed and naive hESCs, Streptavidin (SA) and
FLAG pulldown were performed in WIBR2-OCT43xFLBio and WIBR2-BirA (control) ESCs, and two replicates of endogenous OCT4 antibody pulldown were
performed in wild-type WIBR2 and WIBR3 hESCs (compared to IgG control). All
cell lines for AP-MS were expanded to about ﬁfteen conﬂuent 15 cm diameter
dishes before harvest. For primed hESCs, the colonies were collected by Collagenase IV (Gibco, 1 mg/ml) treatment and separated from feeder cells by washes
with medium and sedimentation by gravity. For naïve hESCs, SA and 3xFLAG
pulldown were performed in naive WIBR2-OCT43xFLBio and WIBR2-BirA hESCs
infected with DOX-inducible KLF2 and NANOG transgenes and cultured in 2i/L/
DOX+RI, and endogenous OCT4 antibody pulldown was performed in hESCs
cultured in 4i/L/A medium (omission of GSK3β inhibitor IM-12) cocktail to
achieve enhanced proliferation, as previously described15. Naïve hESCs were collected by dissociation using 3–5 min treatment with Accutase and centrifugation in
ﬁbroblast medium.
Nuclear extraction and afﬁnity puriﬁcation of 3xFLBio-tagged OCT4-associated
complexes were performed as previously described76. Brieﬂy, the cell pellets were
resuspended in ice-cold hypotonic buffer A (10 mM HEPES, pH 7.9, 1.5 mM
MgCl2, 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF and protease inhibitor cocktail
(Roche) and incubated for 10 min on ice. The sample was centrifuged at 4500 × g
for 5 min at 4 °C and the pellet containing nuclei was washed by resuspending with
3 ml of ice-cold buffer A and centrifuging at 25,000 × g for 20 min at 4 °C. Then,
nuclei were resuspended with 3 ml of ice-cold nuclear extract buffer C (20 mM
HEPES, pH 7.9, 20% glycerol (v/v), 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
0.5 mM DTT, 0.2 mM PMSF, and protease inhibitor cocktail) and incubated at 4 °C
for 30 min. Insoluble materials were pelleted by centrifugation at 25,000 × g for
20 min at 4 °C. The supernatant was collected as nuclear extract (NE) and dialyzed
against buffer D (20 mM HEPES, pH 7.9, 20% glycerol (v/v), 100 mM KCl, 0.2 mM
EDTA, 0.5 mM DTT, 0.2 mM PMSF) at 4 °C for 3 h. Then, 0.1 ml of Protein G
agarose (Roche Diagnostic) equilibrated in buffer D containing 0.02% NP40 (buffer
D-NP) was added to nuclear extracts in 15 ml tubes (BD Falcon), in the presence
Benzonase (25 U/mL, Millipore 70664), and incubated/precleared for 1 h at 4 °C
with continuous mixing. For SA-IP, nuclear extracts were incubated with
streptavidin-agarose beads (200 uL beads per IP, Invitrogen, 15942-050) and
rotated for 6 h at 4 °C. For FLAG-IP, precleared extracts were incubated with preequilibrated ANTI-FLAG M2 afﬁnity gel (200 uL slurry per IP, Sigma, F2426) for
3 h at 4 °C. For OCT4 antibody IP, precleared extracts were incubated with 20 ug
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OCT4 primary antibody (Santa Cruz, sc-5279) or mouse IgG (Millipore 12–371)
overnight with rotation at 4 °C, then incubated with Protein G agarose beads for
another 2 h. For all samples after beads incubation, ﬁve washes were performed
with buffer D-NP. Bound material was eluted by boiling for 5 min in Laemmli
buffer and fractionated on a 10% SDS-PAGE. The gel lanes were horizontally cut
into 8–10 pieces and each piece was subjected to digestion with porcine trypsin
(Promega) as previously described76. The resulting peptides from each piece were
dried down and analyzed by LC-MS/MS.
Mass spectrometry and proteomics data analysis. The samples were reconstituted in 5–10 μl of HPLC solvent A (2.5% acetonitrile, 0.1% formic acid). A
nano-scale reverse-phase HPLC capillary column was created by packing 5 μm
C18 spherical silica beads into a fused silica capillary (100 μm inner diameter × 12
cm length) with a ﬂame-draw tip. After equilibrating the column each sample was
loaded onto the column. A gradient of acetonitrile from 2.5 to 97.5% was used to
elute the peptides. As peptides eluted, they were subjected to electrospray ionization and then they entered into an LTQ-Orbitrap-Velos mass spectrometer
(Thermo Finnigan) with collision-induced dissociation (CID). Eluting peptide were
detected, isolated, and fragmented to produce a tandem mass spectrum of speciﬁc
fragment ions for each peptide. MS data were processed by Thermo Proteome
Discoverer software with SEQUEST engine against Swiss-Prot human protein
sequence database (available at https://www.uniprot.org/).
Outputs of protein identiﬁcation from Proteome Discoverer were imported into
a local Microsoft Access database. Duplicated records were removed by unique
protein symbol. Common contamination proteins (trypsin, keratins, Actin,
Tubulins) were removed, and protein lists were ﬁltered by identiﬁcation score >10,
and number of identiﬁed peptides >2. A protein needed to be identiﬁed in three out
of four experiments to be considered an interactor candidate. Proteins present in
more than 20% of CRAPome37 (available at http://www.crapome.org/) experiments
were removed prior to calculation of empirical p-values. OCT4 interactors were
chosen from the list of proteins with a combined cumulative probability (CCP)
score as described previously38, with the following minor modiﬁcations to the
algorithm. We multiplied the ratio of spectral counts between pull-down and
control experiments by the number of spectral counts in pull-down experiments
prior to calculation of the empirical p-value. This rewards proteins with high
spectral counts in pull-down experiments, which is necessary when working with a
more sensitive MS platform. A false-discovery-rate (FDR) of 0.1 was applied as the
signiﬁcance cutoff of OCT4 interactors.
Co-immunoprecipitation (co-IP) and western blot. Co-IP in regular condition
was performed with the same protocol of OCT4 antibody IP-MS experiments but
with a lower number of cells. Usually, conﬂuent 15 cm diameter dishes of WIBR2
and WIBR3 cells in the primed and naïve (4i/L/A or 5i/L/A) conditions were
harvested for co-IP. In high-salt co-IP, the cell nuclei were harvest with the sample
protocol of IP-MS experiment. Then proteins were extracted with buffer C (containing 420 mM NaCl), incubated with the antibody overnight, and with Protein G
agarose beads for another 2 h. Beads were washed four times with buffer C. The
following antibodies were used: OCT4 (2 ug per IP, Santa Cruz, sc-5279), BRG1 (2
ug per IP, Santa Cruz, sc-17796), BRM (2 ug per IP, Bethyl, A301-015A), and the
same amount of mouse IgG (Millipore, 12–371) or rabbit IgG (Millipore, PP64) as
a control. The IPed samples were boiled with Laemmli/SDS Buffer.
For western lot analysis of protein expression in primed and naïve (5i/L/A)
hESCs, cells from a conﬂuent six-well were harvested and resuspended in
radioimmunoprecipitation assay (RIPA) buffer, then incubated on ice for 20 min.
Whole-cell extract concentration was measured by Bradford assay (Pierce, 23236).
Proteins were balanced and subject to SDS-PAGE analysis. Primary antibodies
used were FLAG (Sigma, F1804), V5 (Invitrogen, #1030648), Streptavidin-HRP
Conjugate (diluted in TBS/T buffer, GE Healthcare, RPN1231), GAPDH (1:5000,
Proteintech, 10494-1-AP), ACTIN (1:5000, Sigma, A5441), L1TD1 (Sigma,
HPA030064), SMC1A (Abcam, ab137707), SMC3 (Santa Cruz, sc-8198), MSH2
(Santa Cruz, sc-494), MSH6 (BD Biosciences, 610918), BAF155 (Santa Cruz, sc32763), OCT4 (Santa Cruz, sc-5279). SNF2L (Cell Signaling Tech., #12483), BRM
(Bethyl, A301-015A), BRG1 (Santa Cruz, sc-17796), SNF2H (Santa Cruz, sc13054), BAF47 (Bethyl, A301-087A), BAF53A (Santa Cruz, sc-137062), BAF60B
(Santa Cruz, sc-101162), BAF60A (Santa Cruz, sc-514400), BAF170 (Santa Cruz,
sc-17838), SOX2 (R&D systems, AF2018), KLF4 (R&D Systems, AF3640),
NANOG (Abcam, ab109250), TFAP2C (Santa Curz, sc-12762). If not speciﬁed,
primary antibodies were diluted by 1:1000 in TBS/T buffer with 5% bovine serum
albumin. BEND3 primary antibody is kindly provided by Dr. Supriya Prasanth
from University of Illinois at Urbana–Champaign.
Flow cytometry analysis. Cells were single cell dissociated using TrypLE Express
and washed once in FACS buffer [PBS supplemented with 5% FBS]. The cells were
then resuspended in 100 μL fresh FACS buffer, and incubated with antibodies for
30 min on ice. The following naïve-speciﬁc cell-surface antibodies were used: antiSUSD2-PE, 1:100 (BioLegend, 327406) and anti-CD75-eFluor 660, 1:100 (Thermo
Fisher, 50-0759-42). Following antibody incubation, the cells were washed once
with FACS buffer, resuspended in fresh FACS buffer, and passed through a cell
strainer. Cell debris was excluded by FSC vs. SSC gates and single cells were gated
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by FSC-A vs. FSC-W. Naïve cell-surface markers were analyzed with anti-CD75eFluor 660 (APC channel) and anti-SUSD2-PE. Primed cells and unstained cells
that have undergone the same procedures were used as controls. Flow cytometry
analysis was performed using a BD LSRFortessa X-20 and the data were analyzed
using the FlowJo software.
BRM and BRG1 CRISPR targeting. Guide RNAs (gRNAs) aimed at introducing
out-of-frame indels to trigger nonsense-mediated decay of the transcripts of the
human BRM (SMARCA2) and BRG1 (SMARCA4) genes were designed and validated in K562 cells by the Genome Engineering and iPSC center (GEIC) at
Washington University. In short, synthetic gRNAs (Supplementary Data 6) were
complexed with recombinant Cas9 protein and nucleofected into K562 cells.
Transfected cells were harvested and lysed 48–72 h post-nucleofection. Each target
region was PCR ampliﬁed, indexed, and analyzed on a MiSeq for indel rate,
indicative of cleavage activity. The most efﬁcient gRNAs for each target (sp4 and
sp13) were selected for nucleofection into hESCs. 1.5 × 106 primed H9 hESCs were
transfected with 0.5 µg pmaxGFP control vector, 300 pmol gRNA, and 192 pmol
Cas9 protein. gRNA complexes targeting BRM or BRG1 were transfected into
primed hESC by nucleofection using the Amaxa P3 Primary Cell 4D-Nucleofector
X Kit and 4D-Nucleofector device with program CA-137 (Lonza). Forty eight
hours after nucleofection, the cells were single cell dissociated and sorted for GFPexpressing (~15%) cells using a Sony H800 ﬂow cytometry system. Clonal lines
were analyzed by NGS for presence of insertion–deletions (indels) around the cut
site. Samples that exhibited a mixed indel ratio were discarded. Primed BRM+/+,
BRM+/−, or BRM−/− hESCs were converted to naïve pluripotency in 5i/L/A and
further expanded in PXGL medium, which supports enhanced clonal expansion.
1 × 106 wild-type (WT) and BRM−/− naïve hESCs were then transfected with 1 µg
pmaxGFP, 300 pmol gRNA targeting BRG1, and 192 pmol Cas9 protein with
GeneJuice following manufacturer’s instructions (Millipore, #70967). GFPexpressing cells were sorted after 48 h, and pools were harvested for NGS two
passages later to assess indel frequencies. To generate clonal lines of naïve
BRG1−/− hESCs, WT and BRM+/− naïve hESCs were transfected with 1 ug
pmaxGFP, 300 pmol gRNA targeting BRG1, and 192 pmol Cas9 protein with
GeneJuice, and GFP-expressing cells were FACS sorted 48 h post-transfection.
Individual sorted cells were replated on inactivated MEFs in 96-well plates in PXGL
and naïve media were replaced every 2 days. Individual colonies were picked and
expanded in 24-well plates. Mutations were validated by puriﬁed genomic DNA in
the GEIC at Washington University and the absence of BRG1 protein was validated
by Western blotting.
Knockdown by lentiviral shRNAs. VSV-glycoprotein pseudotyped lentiviral
vector particles were produced by co-transfection of HEK293T cells with packaging
and envelope plasmids as previously described77. The pLKO.1-puro (SIGMA)
plasmids targeting BRM (TRCN0000358828, TRCN0000020329,
TRCN0000367881), BRG1 (TRCN0000015549, TRCN0000015550) and two NonMammalian shRNA Control Plasmid (SIGMA, #SHC002 and #SHC016) were
used. Viral supernatants were harvested after 48 h and ﬁltered through a 0.45 μm
membrane. WIBR3 hESCs maintained in primed hESC medium and WIBR3 naïve
hESCs maintained in 5i/L/A were infected with the lentivirus in the presence of
6 μg/ml polybrene (Millipore). Infected cells were plated on mitomycin Cinactivated DR4 feeder cells and selected with 0.5 μg/ml of puromycin starting
2 days after transduction. Total RNA was extracted after 5 days of puromycin
selection.
Quantitative real-time PCR. To assess the expression of BirA transgene following
AAVS1 targeting in primed hESCs, total RNA was isolated using the Rneasy Kit
(QIAGEN) and reversed transcribed using the Superscript III First Strand Synthesis kit (Invitrogen). Quantitative RT-PCR analysis was performed in triplicate
using the ABI 7900 HT system with FAST SYBR Green Master Mix (Applied
Biosystems). Gene expression was normalized to GAPDH. Error bars represent the
standard deviation (SD) of the mean of triplicate reactions. Primer sequences are
included in Supplementary Data 6.
RNA-seq analysis. RNA-seq analysis was performed in naïve and primed hESCs
in which the BAF ATPases were genetically perturbed by either shRNA-mediated
knockdown of WIBR3 cells and CRISPR/Cas9-mediated knockout of H9 cells.
Total RNA was extracted using E.Z.N.A. Total RNA kit (Omega Bio-Tek, R6834)
with DNase I following the manufacturer’s instructions. Samples were prepared
according to library kit manufacturer’s protocol, indexed, pooled, and sequenced
on an Illumina HiSeq at the Genome Technology Access Center of Washington
University in St. Louis. Single-end reads with 50 bp length were generated from the
knockdown experiment of WIBR3 cells and paired-end reads with 150 bp length
were generated from the knockout experiment of H9 cells.
RNA-seq data processing. RNA-seq data from public resources and our study
(see Supplementary Data 6) were processed together. Brieﬂy, single-end reads were
aligned to the human genome using TopHat (v2.0.10) and Bowtie2 (v2.1.0) with
the default parameter settings. Paired-end reads were aligned to the human genome
using STAR (v2.5.3) with the default parameter settings. The UCSC hg38 human
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genome, as well as the transcript annotation, was downloaded from the iGenomes
site. The aligned bam ﬁles were sorted. Transcript assembly and differential
expression analyses were performed using Cufﬂinks (v2.1.1). Assembly of novel
transcripts was not allowed (-G), other parameters of Cufﬂinks followed the default
setting. The summed RPKM (reads per kilobase per million mapped reads, for
single-end RNA-seq) or FPKM (fragments per kilobase per million mapped reads,
for paired-end RNA-seq) of transcripts sharing each gene_id were calculated and
exported by the Cuffdiff program. In the gene expression matrix, a value of RPKM
+0.1 was applied to the samples of single-end data and a value of FPKM+1 was
applied to the samples of paired-end data, to minimize the effect of low-expression
genes. P values were calculated using a t-test. Differentially expressed genes (DEGs)
were by two-sided t-test P value < 0.05 and fold change > 2. Boxplots for expression
were generated using R. P value was calculated from two-sided
Mann–Whitney test.
PCA analysis was performed for RNA-seq data from different batches. Batch
effects were adjusted by ComBat function implemented in the sva Bioconductor
package (v.3.18.0). The expression data matrix was imported by Cluster
3.0 software (http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm) for
PCA analysis. PC values were visualized with the plot3d function in the rgl package
from CRAN. All R scripts were processed on R-Studio platform (v3.6.1).
Transcriptome analyses of human and non-human primate embryos. Figures 4f
and 5g: Processed single-cell RNA-seq data from 3D-cultured human pregastrulation embryos57 (GSE136447) were downloaded. Genes with very low
expression (average(log2(FPKM + 1)) < 1) potentially due to low capture rates over
all cell types and timepoints were removed. Plots representing the average
expression of selected markers by color and the percentage of epiblast cells that
express the marker by point size was generated by using the ‘DotPlot’ function of
the R Seurat package. Expression of C1 and C6 target genes in human embryos
were obtained based on annotation of the BAF peaks (refer to ChIP-seq analysis,
Supplementary Data 3). Boxplots were generated using R.
Supplementary Figure 5c: To examine the expression of C1 and C6 target genes
(Supplementary Data 3) in non-human primate embryos, single-cell pre- and postimplantation cynomolgus monkey gene expression data59 (GSE74767) were
acquired and ﬁltered for mapped unique gene IDs and valid numeric expression
values. Using a one-to-one gene ID lookup table (Nakamura et al. 2016,
Supplementary Data 2), orthologs of expression target genes (from C1 and C6)
were identiﬁed. Each cell’s average expression for all genes in a cluster was plotted
for each developmental stage using R.
ChIP-seq analysis. ChIP-seq was performed on WIBR3 cells cultured in primed
and naïve (5i/L/A) conditions. Cells were single cell dissociated, resuspended in
their respective media at a concentration of 1 million cells/mL, crosslinked in 1%
formaldehyde at 37 °C for 10 min, quenched in glycine (0.125 M) for 5 min, and
resuspended in ice-cold PBS. ChIP was performed following an EZChIP protocol
from Millipore (#17-371). Brieﬂy, about 5 million hESCs were used for each ChIP
experiment. Sonication was performed on a Bioruptor system, with 30 s ON, 30 s
OFF, 30 cycles, high amplitude. The primary antibodies used for ChIP were: BRG1
(5 ug, Abcam, ab110641), BRM (3 ug, Cell Signaling Tech., #11966), BAF155 (3 ug,
homemade in Dr. Kadoch’s lab), and SOX2 (5 ug, R&D Systems, AF2018). 10% of
sonicated genomic DNA was used as ChIP input.
For BRG1, BRM, and BAF155, library prep and sequencing were performed on
Illumina NextSeq 500 in the Molecular Biology Core Facilities at the Dana-Farber
Cancer Institute. Data with 75 bp single-end reads were obtained. For SOX2, ChIP
libraries were prepared using the NEBNext Ultra II DNA library prep kit and index
primers sets (NEB, #7645 S, #E7335S) followed the standard protocol. Massively
parallel sequencing was performed by Novogene Co. with the Illumina HiSeq 4000
Sequencer according to the manufacturer’s protocol. Libraries were sequenced as
150 bp paired-end reads.
CUT&Tag analysis. Cleavage Under Targets and Tagmentation (CUT&Tag)
analysis to interrogate KLF4 binding in WIBR3 primed and naïve (5i/L/A) hESCs
was performed as described previously78 with minor modiﬁcations. Brieﬂy, 200,000
cells per sample replicate were washed in Wash Buffer [1 mL 1 M HEPES pH 7.5
(Sigma–Aldrich, H3375), 1.5 mL 5 M NaCl (Sigma–Aldrich, S5150), 12.5 μL 2 M
Spermidine (Sigma–Aldrich, S2501), 1 Roche Complete Protease Inhibitor EDTAFree tablet (Sigma–Aldrich, 5056489001), and bring the ﬁnal volume to 50 mL with
dH2O], then immobilized on 10 ul of Concanavalin A-coated beads (Bangs
Laboratories). Cells were cleared on a magnetic rack, then permeabilized with Digwash buffer [20 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM Spermidine and 1×
protease inhibitor cocktail containing 0.05% Digitonin]. The cells were then
incubated with primary KLF4 antibody (R&D, AF3640, 1:100) at 4 °C overnight.
The primary antibody was cleared on a magnetic rack. Rabbit anti-Goat IgG secondary antibody was diluted 1:100 in Dig-wash buffer and incubated at RT for an
hour. Cells were cleared on a magnetic rack and washed with 1 mL of Dig-wash
buffer. A 1:200 diluted of pA-Tn5 adapter complex was prepared in Dig-300 Buffer
[20 mM HEPES pH 7.5, 300 mM NaCl, 0.5 mM Spermidine and 1× protease
inhibitor cocktail containing 0.05% Digitonin]. Cells were cleared on a magnetic
rack and incubated by adding 100 ul of pA-Tn5 at RT for 1 h. Cells were washed
16

with 1 mL of Dig-300 buffer, resuspended in 300 ul of Tagmentation buffer
[10 mM MgCl2 in Dig-300 Buffer], and incubated at 37 °C for 1 h. 10 ul of 0.5 M
EDTA, 3 ul of 10% SDS, and 2.5 ul of 20 mg/mL Proteinase K was added to each
reaction to stop the tagmentation at 55 °C for an hour. DNA was puriﬁed using
phenol/chloroform/isoamyl alcohol (PCI) extraction followed by chloroform
extraction and precipitated with glycogen and ethanol. DNA was pelleted with a
high-speed spin at 4 °C, washed, air dried for 5 min and resuspended in 50 ul of
double-distilled water (ddH2O). The DNA was then PCR ampliﬁed using i5 and i7
indexing primers, and cleaned up with AMPure XP beads, and the size distribution
and concentration were conﬁrmed using Tapestation. The libraries were then
sequenced on an Illumina NovaSeq S4 2 × 150 platform.
ATAC-seq analysis. ATAC-seq was performed as previously described17 on H9
WT, BRG1+/− and BRG1−/− naïve hESCs, WT, BRG1+/−, and BRG1−/− cells at
day 4 of repriming, and WT primed hESCs. Brieﬂy, cells were harvested by TrypLE
Express dissociation and centrifuged at 500 RCF for 5 min at 4 °C. After aspirating
the supernatant, cells were washed once with cold PBS containing 0.04% BSA. Cell
pellets were resuspended in 300 μl DNaseI (ThermoFisher, EN0521) solution
[20 mM Tris pH 7.4, 150 mM NaCl, 1× reaction buffer with MgCl2, 0.1U/ul
DNaseI] on ice for 5 min. After DNase treatment, 1 ml PBS containing 0.04%BSA
was added and cells were centrifuged at 500 rcf for 5 min at 4 °C. Another two
washes were done in 1 ml PBS containing 0.04% BSA. Cell pellets were resuspended
in 100 ul ATAC-seq RSB [10 mM Tris pH 7.4, 10 mM NaCl, 3 mM MgCl2 in water]
consisting of 0.1% NP40, 0.1% Tween-20, and 0.01% digitonin by pipetting up and
down and incubating on ice for 3 min. After lysis, 1 mL of ATAC-seq RSB containing 0.1% Tween-20 was added and inverted with the lysis reaction. Then, nuclei
were pelleted by centrifugation at 800 RCF for 5 min at 4 °C. Supernatant was
removed, and the nuclei were resuspended in 20 µL 2× TD buffer [20 mM Tris pH
7.6, 10 mM MgCl2, 20% Dimethyl Formamide]. 50,000 counted nuclei were then
transferred to a tube with 2× TD buffer ﬁlled up to 25 µL. 25 µL of transposition mix
[2.5 µL Transposase (100 nM ﬁnal) (Illunina, 20034197, 16.5 µL PBS, 0.5 µL 1%
digitonin, 0.5 µL 10% Tween-20, and 5 µL water) was added. Transposition reactions were mixed and incubated for 30 min at 37 °C with gentle tapping every 10
min. Reactions were cleaned up with the Zymo DNA Clean and Concentrator-5 kit
(Zymo Research, D4014). The ATAC-seq library was ampliﬁed for nine cycles on a
PCR machine. The PCR reaction was puriﬁed with Ampure XP beads (Beckman
Coulter, A63880) using double size selection following the manufacturer’s protocol,
in which 27.5 µL beads (0.55× sample volume) and 50 µL beads (1.55× sample
volume) were used based on 50 µL PCR reaction. The ATAC-seq libraries were
quantitated by Qubit assays and sequenced by an Illumina NextSeq platform. QC
and analysis on ATAC-seq libraries was performed using AIAP79. The generated
peaks ﬁles for each library were incorporated with bedtools merge and counts on
each peak were quantiﬁed for all libraries using bedtools coverage.
ChIP-seq, CUT&TAG, and ATAC-seq data processing. ChIP-seq and ATAC-seq
data from public resources and our study (see Supplementary Data 6) were processed together with the same settings. Brieﬂy, reads were preprocessed by
trim_galore (v0.6.3) and aligned to the hg38 human genome using the bowtie2
(v2.3.4) program. For single-end reads, the bowtie2 program followed the default
setting. The aligned reads were exported (-F 0 × 04), sorted, duplicates-removed
with samtools (v0.1.19). For paired-end reads, bowtie2 parameters were “-X
1000–no-mixed --no-discordant”. The aligned paired reads were exported (-F 0 ×
04 -f 0 × 02) and sorted with samtools. Duplicates were removed with MarkDuplicates function in the PICARD (v2.14.0) package. All Bam ﬁles were converted to
a binary tiled ﬁle (tdf) and visualized using IGV (v2.7.2) software.
All ChIP-seq peaks were determined by the MACS2 program (v.2.0.10) using
the input ChIP-seq as the control data, and all other parameters followed the
default settings. Peaks of TFs (SOX2, KLF4, OCT4) were called as narrow peaks,
and peaks of histone marks and BAF components were called as broad peaks.
ATAC-seq peaks in naïve and primed hESCs48 were determined by MACS2
program with the default settings. The R package diffbind (v1.16.3) from
bioconductor was used to determine the common ATAC peaks, with a minimal
overlap from 3 (out of 4) replicates. All peaks were annotated using the
annotatePeaks module in HOMER program (v4.11) against the hg38 genome. A
target gene of a called peak was deﬁned as nearest gene’s transcription start site
(TSS) with a distance to TSS less than 20 kb.
The BAF peaks were merged from the highly concordant BRG1 and BAF155
peak regions with the merge function in bedtools (v2.18.1) package in either naïve
or primed hESCs. The common peaks were determined by the intersect function in
bedtools package. Overlapped peaks were deﬁned as a mutual overlap with a
minimal 25% regions covered by each other (-f 0.25 -F 0.25 –e). For all the BAF
peaks determined in naïve and primed hESCs, the presence or absence of
overlapping peaks with OCT4 and the H3 histone marks was determined using the
criteria above for the intersect function in bedtools to create a binary table of
overlaps for each BAF peaks. The interactions among the BAF binding sites, OCT4
binding sites, and histone modiﬁcations were categorized by k-means clustering
using R with the number of clusters set at k = 10 and parameters iter.max = 1000
and nstart = 1000. Clusters were annotated based on the pattern of histone marks
at each cluster. Motif analysis was performed for each cluster with the
ﬁndMotifsGenome module (-size given) in the HOMER program (v4.11).
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Heatmaps and mean intensity curves of ChIP-seq data at speciﬁc genomic regions
were plotted by the NGSplot tools (v2.61, available at https://github.com/shenlabsinai/ngsplot) centered by the middle point “(start+end)/2” of each region. The
signiﬁcance (P value) assessing the overlap between two groups of genomic regions
was calculated by Fisher-exact test with an alternative hypothesis of greater on R
platform.
For analysis of ATAC-seq data of naïve hESCs and repriming samples, the
ATAC-seq read intensity at BAF peaks was calculated by the diffbind package of R
(v1.16.3). The signiﬁcantly increased or decreased ATAC peaks were obtained by
cutoffs FDR<0.05. The M-A intensity plots were created by the plotMA function in
the diffbind package. The predicted number of ATAC peaks in each BAF cluster
was calculated by the total number of signiﬁcantly regulated peaks multiplied by
the portion of each BAF cluster among total BAF peaks. A P value was calculated
by the ﬁsher-extract test using the R platform.
GO and GSEA analysis. The gene ontology (GO) analysis for the genomic locations of BAF peaks was performed with the GREAT tool (v3.0, http://great.
stanford.edu/). GO analysis for the signiﬁcantly regulated genes was performed
with the DAVID tool (v6.8, https://david.ncifcrf.gov/tools.jsp). P value is from the
right-sided Fisher’s Extract test. Geneset enrichment analysis (GSEA, v3.0, available
at https://www.broadinstitute.org/gsea) was used to determine the enrichment of
ICM- or hESC-signatures in naïve vs. primed hESCs. The gene signatures were
obtained from a published RNA-seq dataset that reports stage-speciﬁc gene
expression in early human embryos53. The normalized enrichment score (NES)
and FDR q value were indicated for each enrichment test.

Data availability
The data that support this study are available from the corresponding authors upon
reasonable request. The OCT4 afﬁnity puriﬁcation mass spectrometry data have been
deposited to the ProteomeXchange Consortium via the PRIDE partner repository with
the dataset identiﬁer PXD026556. The ATAC-seq, ChIP-seq, CUT&Tag, and RNA-seq
data generated in this study have been deposited in the Gene Expression Omnibus (GEO)
database under accession codes GSE147751 and GSE168002. The ATAC-seq and
TFAP2C ChIP-seq data (GSE101074), OCT4 and H3K27ac ChIP-seq data (GSE69647),
and H3K4me3 and H3K27me3 ChIP-seq data (GSE59435) in naïve and primed hESCs
were analyzed in this study. The ATAC-seq and RNA-seq data of human embryos
(GSE101571), and ATAC-seq and ChIP-seq data (GSE122631) of human NPCs, and
SOX2 ChIP-seq data (GSE69479) in human NPCs were analyzed in this study. Source
data are provided with this paper.
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